Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02372799 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 473
- Enrollment target
NCT02372799 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 473 participants.
The verdict
NCT02372799, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 473 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.
Interventions
- DRUG Placebo
- DRUG Fluoxetine
- DRUG Vilazodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 473 participants |
| Start Date | 2015-02-28 |
| Est. Completion | 2018-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02372799
The ClinicalTrials.gov registry entry for NCT02372799 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 473 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02372799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02372799 about?
NCT02372799 is a clinical study titled "Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)". The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.
What is the current status of trial NCT02372799?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 473 participants. The study started on 2015-02-28. Estimated completion is 2018-09-11.
What interventions are being tested in trial NCT02372799?
The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG), Vilazodone (DRUG).
Who is sponsoring clinical trial NCT02372799?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.